Sec Form 4 Filing - Sofinnova Partners SAS @ CinCor Pharma, Inc. - 2022-01-11

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sofinnova Partners SAS 2. Issuer Name and Ticker or Trading Symbol CinCor Pharma, Inc. [ CINC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 7-11 BOULEVARD HAUSSMANN 3. Date of Earliest Transaction (MM/DD/YY) 01/11/2022 (Street) PARIS, I075009 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 01/11/2022 C 3,867,646 A 3,867,646 I By Sofinnova Capital IX( 2 ) Common Stock 01/11/2022 P 220,000 A $ 16 4,087,646 I By Sofinnova Capital IX( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) 01/11/2022 C 9,999,999 ( 1 ) ( 1 ) Common Stock 2,941,176 $ 0 0 I By Sofinnova Capital IX( 2 ) Series B Preferred Stock ( 1 ) 01/11/2022 C 3,150,000 ( 1 ) ( 1 ) Common Stock 926,470 $ 0 0 I By Sofinnova Capital IX( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sofinnova Partners SAS 7-11 BOULEVARD HAUSSMANN PARIS, I075009 X Sofinnova Capital IX 7-11 BOULEVARD HAUSSMANN PARIS, I075009 X Signatures Sofinnova Partners SAS, By /s/ Monique Saulnier, Managing Partner 01/13/2022 Signature of Reporting Person Date Sofinnova Capital IX, By: Sofinnova Partners SAS, its management company, By /s/ Monique Saulnier, Managing Partner 01/13/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date. ( 2 )The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may bedeemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to theextent of its pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.